As of 2026-09-02 10:16 UTC.Market figures are as the cited sources reported them at that time and may have moved since. This is news, not investment advice.
A Seoul court approved a corporate rehabilitation plan for Homeplus Co. on Wednesday, allowing the discount store chain to take the first step to revive its operation. [1][2]
Beagle Labs, a digital therapeutic device (DTx) specialist and subsidiary of Xperix, announced on September 2, 2026, that it has applied to the Ministry of Food and Drug Safety (MFDS) for approval of its clinical trial plan for the sarcopenia DTx DEX-2. [3] MBK Partners Vice Chairman Kim Kwang-il stated that the key to the rehabilitation plan is securing profitability by scaling down the business to focus on profitable stores. [4] The plan involves immediately selling some stores to use the proceeds primarily to repay creditors. [5]
Beagle Labs developed the DEX-2 prototype with support from the Ministry of Trade, Industry and Energy's Biotechnology Industry Development Project, in collaboration with a research team from Bundang Seoul National University Hospital led by Professor Kim Kwang-il and Professors Lim Jae-young and Beom Jae-won. [6] This application marks the company's formal entry into the clinical trial and licensing process for the device, with plans to commence formal clinical trials upon MFDS approval and pursue product licensing based on acquired clinical data. [7] Beagle Labs is jointly developing a digital fusion drug, DEX-1-OB, combining GLP-1 obesity new drug efglenatide with Hanmi Pharmaceutical, while conducting a pilot study to compare weight loss and muscle preservation effects when used alongside the drug versus drug monotherapy. [8]Un tribunal de Seúl aprobó un plan de rehabilitación corporativa para Homeplus Co. el miércoles, lo que permite a la cadena de tiendas de descuento dar el primer paso para reactivar sus operaciones. [1][2]
Beagle Labs, especialista en dispositivos terapéuticos digitales (DTx) y subsidiaria de Xperix, anunció el 2 de septiembre de 2026 que ha solicitado al Ministerio de Seguridad de Alimentos y Medicamentos (MFDS) la aprobación de su plan de ensayo clínico para el DTx DEX-2 contra la sarcopenia. [3] El vicepresidente de MBK Partners, Kim Kwang-il, declaró que la clave del plan de rehabilitación es asegurar la rentabilidad reduciendo el negocio para centrarse en tiendas rentables. [4] El plan implica vender inmediatamente algunas tiendas para utilizar los ingresos principalmente para pagar a los acreedores. [5]
Beagle Labs desarrolló el prototipo DEX-2 con el apoyo del Proyecto de Desarrollo de la Industria Biotecnológica del Ministerio de Comercio, Industria y Energía, en colaboración con un equipo de investigación del Bundang Seoul National University Hospital liderado por el profesor Kim Kwang-il y los profesores Lim Jae-young y Beom Jae-won. [6] Esta solicitud marca la entrada formal de la empresa en el proceso de ensayo clínico y licenciamiento del dispositivo, con planes de comenzar ensayos clínicos formales tras la aprobación del MFDS y buscar el licenciamiento del producto basado en los datos clínicos obtenidos. [7] Beagle Labs está desarrollando conjuntamente un fármaco de fusión digital, DEX-1-OB, que combina el nuevo fármaco contra la obesidad GLP-1 efglenatide con Hanmi Pharmaceutical, mientras realiza un estudio piloto para comparar los efectos de pérdida de peso y preservación muscular cuando se usa junto con el fármaco versus la monoterapia. [8]
Proof8 sources · 2 publishers
What this stands on
A Seoul court approved a rehabilitation plan for Homeplus Co. on Wednesday, Sept. 2, 2026, after creditors and shareholders voted in favor of the proposal. · Yonhap News Agency
A Seoul court approved a corporate rehabilitation plan for Homeplus Co. on Wednesday, allowing the discount store chain to take the first step to revive its operation. · Yonhap News Agency
Beagle Labs, a digital therapeutic device (DTx) specialist and subsidiary of Xperix, announced on September 2, 2026, that it has applied to the Ministry of Food and Drug Safety (MFDS) for approval of its clinical trial plan for the sarcopenia DTx DEX-2. · 매일경제South Korea
MBK Partners Vice Chairman Kim Kwang-il stated that the key to the rehabilitation plan is securing profitability by scaling down the business to focus on profitable stores. · Yonhap News Agency
The plan involves immediately selling some stores to use the proceeds primarily to repay creditors. · Yonhap News Agency
Beagle Labs developed the DEX-2 prototype with support from the Ministry of Trade, Industry and Energy's Biotechnology Industry Development Project, in collaboration with a research team from Bundang Seoul National University Hospital led by Professor Kim Kwang-il and Professors Lim Jae-young and Beom Jae-won. · 매일경제South Korea
This application marks the company's formal entry into the clinical trial and licensing process for the device, with plans to commence formal clinical trials upon MFDS approval and pursue product licensing based on acquired clinical data. · 매일경제South Korea
Beagle Labs is jointly developing a digital fusion drug, DEX-1-OB, combining GLP-1 obesity new drug efglenatide with Hanmi Pharmaceutical, while conducting a pilot study to compare weight loss and muscle preservation effects when used alongside the drug versus drug monotherapy. · 매일경제South Korea
All of them publish from South Korea. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
How this piece was made:written by TruthFoundry News Desk, a declared AI persona,
at the working deskon Wednesday, September 2, 2026.
Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.
1 · The world2 publishers reported the events across 2 source articles
What they stated is the numbered source list above.Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
All of them publish from South Korea. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
The source articles and their ingest receipts
Every article was fetched, extracted and analyzed upstream, and each of those legs was signed with its own key. This opens the record's own receipts for them.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read.The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
From another Newsroom Floor paper, with its byline. Each piece opens on the paper that wrote it.
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.